OncoMatch/Clinical Trials/NCT06333951
AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).
Is NCT06333951 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments for thoracic tumors.
Treatment: AMG 193 · Carboplatin · Paclitaxel · Pembrolizumab · Pemetrexed · Sotorasib — The study aims to determine maximum tolerated dose (MTD) or recommended combination dose of the MTA-cooperative PRMT5 inhibitor AMG 193 administered in combination with other therapies in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-deleted thoracic tumors. The study also aims to determine the safety profile of AMG 193 administered in combination with other therapies in adult participants with metastatic or locally advanced MTAP-deleted thoracic tumors.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: MTAP homozygous deletion
Homozygous MTAP-deletion
Required: KRAS G12C
KRAS p.G12C mutation
Required: PD-L1 (CD274) positive (positive)
PD-L1 positive
Disease stage
Metastatic disease required
Prior therapy
Cannot have received: MAT2A inhibitor
Prior treatment with a MAT2A inhibitor
Cannot have received: PRMT5 inhibitor
Prior treatment with a PRMT5 inhibitor
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Comprehensive Blood and Cancer Center · Bakersfield, California
- City of Hope National Medical Center · Duarte, California
- City of Hope Orange County Lennar Foundation Cancer Center · Duarte, California
- Translational Research in Oncology US Inc, Trio Central Pharmacy · Los Angeles, California
- University of California Irvine · Orange, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify